MBRX

Company Overview — What Does Moleculin Biotech, Inc. Do?

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech, Inc. (MBRX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Walter V. Klemp and employs approximately 20 people, headquartered in HOUSTON, Texas. With a market capitalization of $12M, MBRX is one of the notable companies in the Healthcare sector.

Moleculin Biotech, Inc. (MBRX) Stock Rating — Reduce (April 2026)

As of April 2026, Moleculin Biotech, Inc. receives a Reduce rating with a composite score of 34.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MBRX ranks #3,348 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Moleculin Biotech, Inc. ranks #508 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MBRX Stock Price and 52-Week Range

Moleculin Biotech, Inc. (MBRX) currently trades at $2.61. The stock gained $0.06 (2.4%) in the most recent trading session. The 52-week high for MBRX is $7.98, which means the stock is currently trading -67.3% from its annual peak. The 52-week low is $0.25, putting the stock 944.1% above its annual trough. Recent trading volume was 55K shares, suggesting relatively thin trading activity.

Is MBRX Overvalued or Undervalued? — Valuation Analysis

Moleculin Biotech, Inc. (MBRX) carries a value factor score of 8/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.86x, versus the sector average of 2.75x.

At current multiples, Moleculin Biotech, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Moleculin Biotech, Inc. Profitability — ROE, Margins, and Quality Score

Moleculin Biotech, Inc. (MBRX) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -397.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -269.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MBRX Debt, Balance Sheet, and Financial Health

Moleculin Biotech, Inc. has a debt-to-equity ratio of 47.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.41x, suggesting adequate working capital coverage. Total debt on the balance sheet is $0. Cash and equivalents stand at $7M.

MBRX has a beta of -2.26, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Moleculin Biotech, Inc. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Moleculin Biotech, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Moleculin Biotech, Inc. reported revenue of $0 and earnings per share (EPS) of $-28.42. Net income for the quarter was $-60M. Operating income came in at $-25M.

In FY 2025, Moleculin Biotech, Inc. reported revenue of $0 and earnings per share (EPS) of $-28.42. Net income for the quarter was $-34M. Operating income came in at $-25M.

In Q3 2025, Moleculin Biotech, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.68. Net income for the quarter was $-25M. Operating income came in at $-6M.

In Q2 2025, Moleculin Biotech, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.15. Net income for the quarter was $-18M. Operating income came in at $-6M.

Over the past 8 quarters, Moleculin Biotech, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing MBRX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MBRX Dividend Yield and Income Analysis

Moleculin Biotech, Inc. (MBRX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MBRX Momentum and Technical Analysis Profile

Moleculin Biotech, Inc. (MBRX) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

MBRX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Moleculin Biotech, Inc. (MBRX) ranks #508 out of 838 stocks based on the Blank Capital composite score. This places MBRX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MBRX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MBRX vs S&P 500 (SPY) comparison to assess how Moleculin Biotech, Inc. stacks up against the broader market across all factor dimensions.

MBRX Next Earnings Date

No upcoming earnings date has been announced for Moleculin Biotech, Inc. (MBRX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MBRX? — Investment Thesis Summary

The quantitative profile for Moleculin Biotech, Inc. suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 8/100 indicates premium valuation. Price momentum is positive at 63/100, suggesting the trend favors buyers. High volatility (stability score 33/100) increases portfolio risk.

In summary, Moleculin Biotech, Inc. (MBRX) earns a Reduce rating with a composite score of 34.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MBRX stock.

Related Resources for MBRX Investors

Explore more research and tools: MBRX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MBRX head-to-head with peers: MBRX vs AZN, MBRX vs SLGL, MBRX vs VMD.